KA
RPRX icon

Kearns & Associates’s Royalty Pharma RPRX Stock Holding History

Kearns & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.27M Hold
58,240
– – 1.52% 8
2026
Q1 		$2.79M Sell
58,240
-12,500
-18% -$547K 1.5% 8
2025
Q4 		$2.73M Hold
70,740
– – 1.41% 8
2025
Q3 		$2.5M Hold
70,740
– – 1.32% 8
2025
Q2 		$2.55M Hold
70,740
– – 1.46% 8
2025
Q1 		$2.2M Buy
70,740
+53,055
+300% +$1.68M 1.43% 8
2024
Q4 		$451K Buy
+17,685
New +$469K 0.29% 29

Other funds holding RPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
TIP
Torray Investment Partners Bethesda, Maryland $741M AUM 26.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AIM
Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Kearns & Associates's RPRX Position: Q2 2026 in Review

Kearns & Associates held its Royalty Pharma (RPRX) position steady in Q2 2026 at 58,240 shares worth $3.27M. The position accounts for 1.52% of the portfolio, ranked #8.

Kearns & Associates first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 168 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Kearns & Associates held 58,240 shares of Royalty Pharma worth $3.27M as of Q2 2026.
  • Kearns & Associates left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 1.52% of Kearns & Associates's portfolio in Q2 2026, its #8 holding.
  • Kearns & Associates first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 168 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Kearns & Associates's 13F filing for Q2 2026, filed 23 Jul 2026.